Joyce O'Shaughnessy

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

J. O’Shaughnessy, Zheng-Yi Zhou, A. Haiderali, 2023, Advances in Therapy.